19
May

08:00 AM EDT

Chemistry, Manufacturing and Controls

Name: Medicinal Chemistry Strategy Meeting East Coast 2025 (Boston)
Start: 2025-05-08T08:00
End: 2025-05-08T18:00
Location: Le Méridien Boston Cambridge

Strategy Meeting East Coast USA 2026

The premier meeting for all East Coast USA CMC professionals

Le Meridien Cambridge

A MEETING EXPERIENCE UNLIKE ANY OTHER

Fresh CMC Insights

Tired of the same conference experience? Real discussions and genuine networking are often promised, but not always delivered. Proventa International’s Manufacturing Strategy Meetings are designed to avoid the pitfalls of a typical conference, by providing the right environment to make those important connections through interactive roundtable discussions, exclusive networking and keynote panel debates. Join CMC professionals from across the East Coast, in Boston MA, to discover new insights and take your company’s mission to the next level.

What makes our strategy meetings unique?

Roundtable Discussions

Intimate discussions led by renowned industry experts. Have your voice heard and debate alongside like-minded life science executives.

Unrivalled Networking

With senior delegation from big pharma and innovative biotech from across the East Coast, you can network with peers from different locations, all in one place.

Personalised Agenda

Choose the topics that matter to you. Reserve your place at the roundtable discussions and ensure your whole day delivers the insights you need to hear.

Solutions to your Problems

We’ve partnered with the best solution providers to solve your biggest challenges. Engage in pre-arranged, private meetings to address your specific needs and find a tangible solution.

Industry Researched Topics

We guarantee our agenda is up-to-date and mission critical because its designed by you. We speak to our extended network of senior decision makers to ensure the most important topics are discussed.

Senior Decision Makers

The entire strategy meeting is specifically tailored to the needs and challenges of senior life science professionals. Discover how your peers are dealing with the same challenges as you.

Our Facilitators

Our panel of facilitators plays a key role in shaping the agenda for the day. Whilst we’re busy connecting with the best industry experts, take a look at our facilitators.

Anandita Seth

Vice President, Process and Analytical Development Neurogene Inc.

Abizer Harianawala

Vice President, CMC & Technical Operations Alkeus Pharmaceuticals, Inc.

Debasis Patra

Vice President, Head of CMC OliX Pharmaceuticals

Erin O’Brien

Vice President, Pharmaceutical Development Parabilis Medicines

Erin O’Brien is a collaborative, strategic, and solutions-oriented leader responsible for the development and manufacturing of small molecule drug candidates through clinical development and commercial life cycle management. Currently serving as the Head of Process Chemistry at Takeda Pharmaceuticals, she spearheads the development of synthetic molecule drug substances. Before joining Takeda, Erin held significant roles at Biogen, including Executive Director, Head of Small Molecule Development, where she led initiatives in drug product process development, technology transfer, and strategic collaborations. Erin’s career began as a research scientist at Roche Palo Alto, LLC. She then advanced through various roles at Millennium: The Takeda Oncology Company, eventually becoming a Group Leader. Her leadership expanded further at Biogen, where she oversaw the chemical Process Development group, focusing on innovative manufacturing processes and green chemistry. Erin holds a Ph.D. in Organic Chemistry from the University of Pennsylvania and a B.S. in Chemistry from Mount Allison University. She is active in professional circles, including International Consortium of Quality, contributing to developments in green chemistry and pharmaceutical manufacturing. Her published works span multiple journals and book chapters, reflecting her commitment to advancing sustainable and efficient chemical processes.

Gopi Vudathala

Global Head, Regulatory Affairs CMC Incyte Corporation

Dr. Vudathala, Ph.D., is currently Global Head, RA CMC at Incyte Corporation. He was Formerly Executive Director of RA CMC at Intarcia Therapeutics, Head of Quality Advocacy at GSK Vaccines and Global Head of Regulatory CMC at Novartis Vaccines. He was also Associate Vice President of Regulatory Affairs CMC at Sanofi-Aventis. He has extensive experience in CMC regulatory strategy for Global Development and Life-Cycle Management Projects and contributed to over 30 NDA and BLA approvals and 60 INDs. Dr. Vudathala has had numerous interactions with global regulators on project related CMC matters as well as on key ICH initiatives. He has published extensively on drug development and regulatory CMC topics. He was on the Regulatory and Quality Advisory Board at the Parenteral Drug Association and a member of the PDA core team on ICHQ12/ Post Approval Changes. He was also previously Vice Chair of the Technical Development and Operations Committee at PhRMA and an active member of the PhRMA CTD Quality Task Force, Genotoxic Impurities Task Force, and a working group member of the FDA Subcommittee for Pharmaceutical Sciences on Process Analytical Technologies and Quality-by-Design. He was also the Chair of the Regulatory Sciences Section of AAPS. Dr. Vudathala is a well-recognized expert on Regulatory CMC and Quality matters and has made several presentations at AAPS, PDA, IIR, Barnett & Proventa International workshops and conferences on CMC, Regulatory, CTD, Drug Device Combination Products and Genotoxic Impurities topics. Dr. Vudathala graduated from the University of Alberta with a Ph.D. in Pharmaceutics and held positions with the Health Protection Branch, Canada, and Procter & Gamble Pharmaceuticals

Goldi Kaul

Vice President, Head of External Alternative CMC Development Boehringer Ingelheim

Gregg Keaney

Senior Vice President, CMC and Product Development Rapport Therapeutics

Gregory Papastoitsis

Chief Process and Manufacturing Officer Ankyra Therapeutics

Dr. Gregory Zarbis-Papastoitsis is the Chief Process and Manufacturing Officer at Ankyra Therapeutics, an immune-oncology company, where he is responsible for all CMC activities. Prior to Ankyra, he was the EVP of Process and Manufacturing at Compass Therapeutics where he oversaw all CMC activities for a CD137 agonist, which is currently in Phase 1/2 clinical studies. Before he was the SVP of development and manufacturing at Eleven Biotherapeutics where he worked on an IL-1 inhibitor that reached pivotal clinical studies for Dry Eye Disease, and an anti-IL6 antibody (successful IND), for Macular Edema. Earlier, he was Associate Director of Process and Analytical Development at Syntonix Pharmaceuticals, where he was responsible for the early development of a long-lasting Factor IX (ALPROLIX®). He also worked on the commercial process of HUMIRA® (Abbott/Abbvie), on the purification process of ONTAK® , an IL2-diphtheria toxin fusion protein (Seragen), on the early development of an antibody-toxin conjugate (aPSMA-DM1) that reached Phase I clinical trials for prostate cancer and an aCCR2 antibody that was in Phase II clinical trials for autoimmune diseases (Millenium Pharma). He received his PhD in Biology at Binghamton University followed by 3 years of post-doctoral studies at Boston University School of Medicine investigating proteases in Alzheimer disease.

Hagen Cramer

Chief Technology Officer QurAlis

Jamie Gillette

Vice President, Head of Regulatory Cullinan Therapeutics

Jennifer Taillie

Vice President, Business Development US AGC Biologics

Kwame Nti-Addae

Executive Director, Head of CMC Frontier Medicines

Mahesh Padval

Chief Pharmaceutical Development Officer Relay Therapeutics

As Chief Pharmaceutical Development Officer, Mahesh Padval guides transition of the Company’s late research assets into development and oversees pharmaceutical development activities to support regulatory filings and product commercialization. Mahesh brings to Relay Therapeutics nearly 30 years of product development experience in the pharmaceutical industry. Prior to joining Relay Therapeutics, Mahesh was vice president of pharmaceutical sciences and product development at Verastem, Inc. There, he was responsible for preclinical development, CMC and clinical pharmacology activities in support of the company’s development programs through non-clinical, clinical development and regulatory filings, including the approval and commercial launch of COPIKTRA TM. Prior to Verastem, Mahesh held roles of increasing responsibility at Zalicus, Inc., culminating in his role as vice president of preclinical development and formulations. He also held roles at Charles River Discovery and Development Services and Genzyme Transgenics Corporation. Mahesh holds a Ph.D. and M.S. in industrial pharmacy from Massachusetts College of Pharmacy, CSS in administration and management from Harvard University and a Bachelor of Pharmacy from the University of Bombay, India.

Melissa Morandi

Vice President and Head, Global Quality Sumitomo Pharma America, Inc.

Neera Jain

Senior Vice President, CMC PureTech Health

Nelly Viseux

Vice President, Cell Therapies Development, Manufacturing, Supply & Quality Regeneron

Olga Paley

Director, Head US Downstream Process Development Late and Bioconjugation Takeda

Paul Peng

Vice President, CMC City Therapeutics

Robert Gabriel

Board Member, Managing Partner Ashur Capital

Rowshon Alam

Vice President, Chemistry and In-Process Analytics Prime Medicine, Inc.

Seshu Tummala

Vice President, Drug Substance Process Development and Manufacturing Uniquity Bio

Yumiko Mizuno

Head, Plasma-Derived Therapies (PDT) Drug Product Development Takeda

Yu Qian

Director, Head of Analytical Project Leads & Cell Therapies Novartis

First name	Last name	Job title	Company name	Photo URL	Bio Position
Anandita	Seth	Vice President, Process and Analytical Development	Neurogene Inc.	https://proventainternational.com/wp-content/uploads/2022/05/avatar.jpg
Abizer	Harianawala	Vice President, CMC & Technical Operations	Alkeus Pharmaceuticals, Inc.	https://proventainternational.com/wp-content/uploads/2020/01/Abizer-Harianawala-2.jpg
Debasis	Patra	Vice President, Head of CMC	OliX Pharmaceuticals	https://proventainternational.com/wp-content/uploads/2024/12/DEBASIS-PATRA-1.jpg	Dr. Debasis Patra has doctoral and post-doctoral research experience in novel method development and total synthesis of natural products. He has been working in the pharma/biotech industry for the last 25 years, leading teams of scientists and engineers for the process development and manufacturing of small molecules, peptides, oligonucleotides, etc. Currently he is heading the CMC team at OliX Pharmaceuticals and is responsible for all activities related to drug substance and drug product development and manufacturing to support multiple clinical stage programs (Phase 1/2) in several disease areas, such as ophthalmology, metabolic, dermatology, hair loss, etc.
Erin	O’Brien	Vice President, Pharmaceutical Development	Parabilis Medicines	https://proventainternational.com/wp-content/uploads/2025/04/Erin-OBrien.jpg	Erin O’Brien is a collaborative, strategic, and solutions-oriented leader responsible for the development and manufacturing of small molecule drug candidates through clinical development and commercial life cycle management. Currently serving as the Head of Process Chemistry at Takeda Pharmaceuticals, she spearheads the development of synthetic molecule drug substances. Before joining Takeda, Erin held significant roles at Biogen, including Executive Director, Head of Small Molecule Development, where she led initiatives in drug product process development, technology transfer, and strategic collaborations. Erin’s career began as a research scientist at Roche Palo Alto, LLC. She then advanced through various roles at Millennium: The Takeda Oncology Company, eventually becoming a Group Leader. Her leadership expanded further at Biogen, where she oversaw the chemical Process Development group, focusing on innovative manufacturing processes and green chemistry. Erin holds a Ph.D. in Organic Chemistry from the University of Pennsylvania and a B.S. in Chemistry from Mount Allison University. She is active in professional circles, including International Consortium of Quality, contributing to developments in green chemistry and pharmaceutical manufacturing. Her published works span multiple journals and book chapters, reflecting her commitment to advancing sustainable and efficient chemical processes.
Gopi	Vudathala	Global Head, Regulatory Affairs CMC	Incyte Corporation	https://proventainternational.com/wp-content/uploads/2022/08/Gopi-Vudathala-1.jpg	Dr. Vudathala, Ph.D., is currently Global Head, RA CMC at Incyte Corporation. He was Formerly Executive Director of RA CMC at Intarcia Therapeutics, Head of Quality Advocacy at GSK Vaccines and Global Head of Regulatory CMC at Novartis Vaccines. He was also Associate Vice President of Regulatory Affairs CMC at Sanofi-Aventis. He has extensive experience in CMC regulatory strategy for Global Development and Life-Cycle Management Projects and contributed to over 30 NDA and BLA approvals and 60 INDs. Dr. Vudathala has had numerous interactions with global regulators on project related CMC matters as well as on key ICH initiatives. He has published extensively on drug development and regulatory CMC topics. He was on the Regulatory and Quality Advisory Board at the Parenteral Drug Association and a member of the PDA core team on ICHQ12/ Post Approval Changes. He was also previously Vice Chair of the Technical Development and Operations Committee at PhRMA and an active member of the PhRMA CTD Quality Task Force, Genotoxic Impurities Task Force, and a working group member of the FDA Subcommittee for Pharmaceutical Sciences on Process Analytical Technologies and Quality-by-Design. He was also the Chair of the Regulatory Sciences Section of AAPS. Dr. Vudathala is a well-recognized expert on Regulatory CMC and Quality matters and has made several presentations at AAPS, PDA, IIR, Barnett & Proventa International workshops and conferences on CMC, Regulatory, CTD, Drug Device Combination Products and Genotoxic Impurities topics. Dr. Vudathala graduated from the University of Alberta with a Ph.D. in Pharmaceutics and held positions with the Health Protection Branch, Canada, and Procter & Gamble Pharmaceuticals
Goldi	Kaul	Vice President, Head of External Alternative CMC Development	Boehringer Ingelheim	https://proventainternational.com/wp-content/uploads/2026/02/Goldi-Kaul.png
Gregg	Keaney	Senior Vice President, CMC and Product Development	Rapport Therapeutics	https://proventainternational.com/wp-content/uploads/2026/02/Gregg-Keaney.png
Gregory	Papastoitsis	Chief Process and Manufacturing Officer	Ankyra Therapeutics	https://proventainternational.com/wp-content/uploads/2025/02/Gregory-Papastoitsis.jpg	Dr. Gregory Zarbis-Papastoitsis is the Chief Process and Manufacturing Officer at Ankyra Therapeutics, an immune-oncology company, where he is responsible for all CMC activities. Prior to Ankyra, he was the EVP of Process and Manufacturing at Compass Therapeutics where he oversaw all CMC activities for a CD137 agonist, which is currently in Phase 1/2 clinical studies. Before he was the SVP of development and manufacturing at Eleven Biotherapeutics where he worked on an IL-1 inhibitor that reached pivotal clinical studies for Dry Eye Disease, and an anti-IL6 antibody (successful IND), for Macular Edema. Earlier, he was Associate Director of Process and Analytical Development at Syntonix Pharmaceuticals, where he was responsible for the early development of a long-lasting Factor IX (ALPROLIX®). He also worked on the commercial process of HUMIRA® (Abbott/Abbvie), on the purification process of ONTAK® , an IL2-diphtheria toxin fusion protein (Seragen), on the early development of an antibody-toxin conjugate (aPSMA-DM1) that reached Phase I clinical trials for prostate cancer and an aCCR2 antibody that was in Phase II clinical trials for autoimmune diseases (Millenium Pharma). He received his PhD in Biology at Binghamton University followed by 3 years of post-doctoral studies at Boston University School of Medicine investigating proteases in Alzheimer disease.
Hagen	Cramer	Chief Technology Officer	QurAlis	https://proventainternational.com/wp-content/uploads/2026/02/Hagen-Cramer.png
Jamie	Gillette	Vice President, Head of Regulatory	Cullinan Therapeutics	https://proventainternational.com/wp-content/uploads/2022/07/Jamie-Gillette-2.jpg	Jamie Gillette is Vice President, Head of Regulatory Affairs at Cullinan Oncology of Cambridge, Massachusetts. She is responsible for Regulatory strategy and operations for all Cullinan pipeline products. Jamie possesses 20+ years of global drug development, clinical trials, and Regulatory experience and has held leadership positions at multiple organizations in the biopharmaceutical industry. She has experience throughout the product life cycle, from INDs through Marketing Applications and across multiple therapeutic areas including oncology, inflammation, and vaccines. As a community leader, Jamie has been an instructor and avid student in Budo Taijutsu for over 10 years. She is also Vice President of the Howard County Veterans Foundation whose mission is to develop and construct the Howard County Veterans Monument in Columbia, Maryland.
Jennifer	Taillie	Vice President, Business Development US	AGC Biologics	https://proventainternational.com/wp-content/uploads/2026/01/Jennifer-Taillie.jpg
Kwame	Nti-Addae	Executive Director, Head of CMC	Frontier Medicines	https://proventainternational.com/wp-content/uploads/2025/04/Kwame-Nti-Addae.jpg	Kwame is a pharmaceutical executive with over 15 years of experience in CMC, formulation, and process development. As Executive Director at Frontier Medicines, he leads Drug Substance, Drug Product, Analytical, and Supply Chain functions. At Lyndra Therapeutics, he played a key role in advancing long-acting oral dosage forms through pivotal trials. He has also held key roles at Ironwood, Cyclerion, and Vertex, driving preclinical and clinical programs and regulatory submissions. Known for his technical expertise, strategic leadership, and dedication to innovation and inclusion, Kwame delivers impactful results across early-stage development through to commercial readiness.
Mahesh	Padval	Chief Pharmaceutical Development Officer	Relay Therapeutics	https://proventainternational.com/wp-content/uploads/2023/03/Mahesh-Padval-1.jpg	As Chief Pharmaceutical Development Officer, Mahesh Padval guides transition of the Company’s late research assets into development and oversees pharmaceutical development activities to support regulatory filings and product commercialization. Mahesh brings to Relay Therapeutics nearly 30 years of product development experience in the pharmaceutical industry. Prior to joining Relay Therapeutics, Mahesh was vice president of pharmaceutical sciences and product development at Verastem, Inc. There, he was responsible for preclinical development, CMC and clinical pharmacology activities in support of the company’s development programs through non-clinical, clinical development and regulatory filings, including the approval and commercial launch of COPIKTRA TM. Prior to Verastem, Mahesh held roles of increasing responsibility at Zalicus, Inc., culminating in his role as vice president of preclinical development and formulations. He also held roles at Charles River Discovery and Development Services and Genzyme Transgenics Corporation. Mahesh holds a Ph.D. and M.S. in industrial pharmacy from Massachusetts College of Pharmacy, CSS in administration and management from Harvard University and a Bachelor of Pharmacy from the University of Bombay, India.
Melissa	Morandi	Vice President and Head, Global Quality	Sumitomo Pharma America, Inc.	https://proventainternational.com/wp-content/uploads/2020/02/Melissa-Morandi.jpeg	Track: Outsourcing
Neera	Jain	Senior Vice President, CMC	PureTech Health	https://proventainternational.com/wp-content/uploads/2026/01/Neera-Jain.jpg
Nelly	Viseux	Vice President, Cell Therapies Development, Manufacturing, Supply & Quality	Regeneron	https://proventainternational.com/wp-content/uploads/2026/03/Nelly-Viseux.jpg
Olga	Paley	Director, Head US Downstream Process Development Late and Bioconjugation	Takeda	https://proventainternational.com/wp-content/uploads/2026/04/Olga-Paley.jpg
Paul	Peng	Vice President, CMC	City Therapeutics	https://proventainternational.com/wp-content/uploads/2025/01/Paul-Peng.jpg	Paul Peng, Ph.D., has about 20 years of experience in the oligonucleotide industry. Dr. Peng is currently leading the CMC function at City Therapeutics for second generation siRNA therapeutics. In his previous roles he made key CMC contributions to support early and late stage development and regulatory filings for oligonucleotide therapeutics (siRNAs, ASOs and RNA editing oligonucleotides) in small and large biotechnology companies including Alnylam, Stoke, Biogen and Korro. With a Ph.D. in nucleoside/nucleotide chemistry from McGill University, he is dedicated to
Robert	Gabriel	Board Member, Managing Partner	Ashur Capital	https://proventainternational.com/wp-content/uploads/2025/04/Robert-Gabriel-2.jpg
Rowshon	Alam	Vice President, Chemistry and In-Process Analytics	Prime Medicine, Inc.	https://proventainternational.com/wp-content/uploads/2026/02/Rowshon-Alam.jpg
Seshu	Tummala	Vice President, Drug Substance Process Development and Manufacturing	Uniquity Bio	https://proventainternational.com/wp-content/uploads/2026/01/Seshu-Tummala.jpg
Yumiko	Mizuno	Head, Plasma-Derived Therapies (PDT) Drug Product Development	Takeda	https://proventainternational.com/wp-content/uploads/2025/04/Yumiko-Mizuno.jpg	Dr. Yumiko Mizuno is the Head of Plasma-Derived Therapies Drug Product Development at Takeda, where she is responsible for all activities related to drug product and combination product development, as well as leading the early-stage portfolio. With over 14 years of experience in R&D CMC at Takeda, she brings deep expertise across all phases of development for a range of modalities. Dr. Mizuno has a proven track record of successfully leading diverse cross-functional and cross-regional teams, fostering collaboration, innovation, and excellence. Previously, she led global R&D strategic planning and change management at Takeda, developing practical skill sets in portfolio strategy and management.
Yu	Qian	Director, Head of Analytical Project Leads & Cell Therapies	Novartis	https://proventainternational.com/wp-content/uploads/2025/04/Yu-Qian.jpg	Yu is the Head of the Cell Therapy Analytical Project team at Novartis. With a background in Immunology and Cancer Immunology, Yu has extensive experience in Analytical Development for Cell Therapies. Yu has a proven track record in developing integrated analytical strategies and guiding teams in creating fit-for- purpose assays to drive innovation and support various cell therapy modalities at different stages. Before joining Novartis, Yu was the Director of Cell Therapy CMC Analytical Innovation and Product Sciences at Takeda Pharmaceuticals and co-founded a start-up prior to joining Takeda.

Anandita Seth, Abizer Harianawala, Debasis Patra, Erin O’Brien, Gopi Vudathala, Goldi Kaul, Gregg Keaney, Gregory Papastoitsis, Hagen Cramer, Jamie Gillette, Jennifer Taillie, Kwame Nti-Addae, Mahesh Padval, Melissa Morandi, Neera Jain, Nelly Viseux, Olga Paley, Paul Peng, Robert Gabriel, Rowshon Alam, Seshu Tummala, Yumiko Mizuno, Yu Qian

Our Past Facilitators

Our panel of facilitators plays a key role in shaping the agenda for the day. Whilst we’re busy connecting with the best industry experts, take a look at our facilitators.

Johan Evenäs

Chief Executive Officer RG Discovery

Fabien Bonhoure

Global Business Project Director SEQENS

Caitlyn Harvey

Vice President, Head of CMC Convergent Therapeutics, Inc.

Daniel Peng

Vice President, Regulatory Affairs CMC Checkpoint Therapeutics

Debasis Patra

Vice President, Head of CMC OliX Pharmaceuticals

Erin O’Brien

Vice President, Pharmaceutical Development Parabilis Medicines

Fue Vang

Director, Analytical Development Candel Therapeutics

Gopi Vudathala

Global Head, Regulatory Affairs CMC Incyte Corporation

Gregory Papastoitsis

Chief Process and Manufacturing Officer Ankyra Therapeutics

Kwame Nti-Addae

Executive Director, Head of CMC Frontier Medicines

Mahesh Padval

Chief Pharmaceutical Development Officer Relay Therapeutics

Matt Barrows

Senior Vice President, CMC & Technical Operations Aviceda Therapeutics

Niels Svenstrup

Senior Vice President, Chemistry & Manufacturing PepGen

Niels Svenstrup has over 20 years of experience in the pharma and biotech industry across various leadership roles in chemistry and manufacturing. He recently founded Creative Molecular Consulting, where he is advising early-stage companies on navigating the transition from discovery to preclinical and clinical development from a CMC, regulatory, and business perspective. Niels has a master’s in cell biology and chemistry, a Ph.D. in organic chemistry, and did his postdoctoral training at The Scripps Research Institute in La Jolla, CA. He joined the pharmaceutical industry as a laboratory leader in medicinal chemistry at Bayer Pharma in Germany in 2000. He later went on to become Head of Department, Medicinal Chemistry at H. Lundbeck’s Neuroscience Drug Discovery Center in Copenhagen, Denmark, before joining Ascendis Pharma as Director of CMC and leader of the team that invented and developed TransCon PTH (now YorviPath), an approved drug in the EU and US for the treatment of hypoparathyroidism. Niels moved to the U.S. in 2017 to take on the role of Senior Vice President, Development at Cydan, a rare disease accelerator located in Cambridge, MA. Most recently, Niels was SVP of Chemistry and Manufacturing at PepGen Inc. from 2021 to 2025

Paul Peng

Vice President, CMC City Therapeutics

Robert Gabriel

Board Member, Managing Partner Ashur Capital

Suresh Tipparaju

Director, Product Development and Clinical Supply Alexion-AstraZeneca Rare Disease

Dr. Suresh Tipparaju is Director of Product Development and Clinical Supply at Alexion-AstraZeneca Rare Disease. He leads development strategy for a portfolio of APIs comprising small molecules, synthetic peptides, and oligonucleotides from early clinical stages up to commercial validation. Over his 15 years of experience in pharmaceutical development and CMC, Suresh was a key contributor and author of marketing applications for four approved medicines currently helping patients in need: Onivyde, Livtencity, Voydeya, and Beyonttra. Before joining AstraZeneca, Suresh worked at Takeda, Shire, and Merrimack Pharmaceuticals. Dr. Tipparaju obtained his PhD in organometallics from the National Chemical Laboratory, India, and was a postdoctoral associate in Nobel laureate (late) Prof. Herbert C. Brown’s lab at the Herbert C. Brown Center for Borane Research at Purdue University, IN. Dr. Tipparaju published over 20 research articles in prestigious peer-reviewed journals and is an inventor on 10 patents. His research interests are in all aspects of CMC and pharmaceutical development.

Stephan Krause

Executive Director, Cell Therapy Global Quality Bristol Myers Squibb

Vikram Sadineni

Vice President, Technical Development & Manufacturing Generate:Biomedicines

Yu Qian

Director, Head of Analytical Project Leads & Cell Therapies Novartis

Yumiko Mizuno

Head, Plasma-Derived Therapies (PDT) Drug Product Development Takeda

Europe

USA East

USA West

Webinars

Dinners & Spotlights

R&D

Manufacturing Boston

Clinical Operations & Clinical Trial Supply Chain Strategy Meeting East Coast – Boston 2024

Chemistry, Manufacturing and Controls

Strategy Meeting East Coast USA 2026

<img class="lazy" decoding="async" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://proventainternational.com/wp-content/uploads/2020/12/location.png" >Le Meridien Cambridge

Fresh CMC Insights

What makes our strategy meetings unique?

Roundtable Discussions

Unrivalled Networking

Personalised Agenda

Solutions to your Problems

Industry Researched Topics

Senior Decision Makers

Our Facilitators

Anandita Seth

Abizer Harianawala

Debasis Patra

Erin O’Brien

Gopi Vudathala

Goldi Kaul

Gregg Keaney

Gregory Papastoitsis

Hagen Cramer

Jamie Gillette

Jennifer Taillie

Kwame Nti-Addae

Mahesh Padval

Melissa Morandi

Neera Jain

Nelly Viseux

Olga Paley

Paul Peng

Robert Gabriel

Rowshon Alam

Seshu Tummala

Yumiko Mizuno

Yu Qian

Our Past Facilitators

Johan Evenäs

Fabien Bonhoure

Caitlyn Harvey

Daniel Peng

Debasis Patra

Erin O’Brien

Fue Vang

Gopi Vudathala

Gregory Papastoitsis

Kwame Nti-Addae

Mahesh Padval

Matt Barrows

Niels Svenstrup

Paul Peng

Robert Gabriel

Suresh Tipparaju

Stephan Krause

Vikram Sadineni

Yu Qian

Yumiko Mizuno

Reasons To Attend Our Strategy Meetings

Fully Interactive Format

Senior Decision Makers

Personalised Agendas

Private and Intimate Networking

Our Agenda

Registration Welcoming

Opening Keynote Presentation

Roundtable

Roundtable Tracks

Refreshment Break

Networking/1-1 Meetings

Roundtable

Roundtable Tracks

AGC BIOLOGICS

Ardena

Le Meridien Cambridge